AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.